Loading resource…

Meinrad Gawaz
Platelets play a crucial role in haemostasis and atherothrombosis, making pharmacological control of platelet hyper-reactivity essential for preventing thrombo-ischaemic complications in atherosclerotic diseases. Current antiplatelet therapies improve outcomes for patients with coronary artery disease but increase bleeding risks. This review discusses the implications of controlling platelet hyper-reactivity for both tissue and vascular inflammation, and it presents novel therapeutic targets and compounds for antiplatelet therapy that may offer safer alternatives to existing treatments.
No account needed